The strongest competitor's data is not good, will the 'weight-loss duo' continue to dominate?

Analysts believe that if Amgen's weight loss drug could achieve a 20% weight loss effect a few years ago, it would have been the best among similar products, but now Eli Lilly and Co and Novo-Nordisk A/S pipeline drugs may achieve or exceed a 25% weight loss effect. Currently, dozens of pharmaceutical companies are actively entering the weight loss drug market, but none have shown the potential to truly challenge the 'weight loss giants'.

wallstreetcnNov 30 21:01 ET

Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ

WSJNov 30 07:00 ET

Boeing, NVIDIA Corp. Share Gains Contribute To Dow's 261-Point Jump

MarketWatchNov 29 11:28 ET

RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $360

Moomoo NewsNov 28 19:31 ET · Ratings

Beigene's commercialized products for multiple indications are included in the new version of the national medical insurance drug list.

Beigene (06160) announced that its self-developed anti-PD-1 antibody drug, Baizean (Tiragolumab injection), and BTK inhibitor, Baiyueze (Zebutini capsule), have added three new indications and one indication has been included in the National Medical Insurance Catalog; Luye Pharma's co-introduced product, Baituowei (Goserelin injection microspheres), has added one indication included in the National Medical Insurance Catalog; Amgen's authorized introduced product, Kyprolis (Carfilzomib for injection), has successfully been renewed. The National Medical Insurance Catalog will be officially implemented starting January 1, 2025. This time the company's products Baizean and Baiyueze.

Sina Hong Kong stocks.Nov 28 19:14 ET

Should You Be Excited About Amgen Inc.'s (NASDAQ:AMGN) 56% Return On Equity?

Yahoo FinanceNov 28 07:00 ET